Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Retained Earnings: 2020-2025

Historic Retained Earnings for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to -$3.0 billion.

  • Apellis Pharmaceuticals' Retained Earnings changed negligibly% to -$3.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.0 billion, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of -$3.0 billion for FY2024, which is 6.97% down from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Retained Earnings stood at -$3.0 billion, which was up 6.25% from -$3.2 billion recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Retained Earnings peaked at -$1.1 billion during Q1 2021, and registered a low of -$3.2 billion during Q2 2025.
  • For the 3-year period, Apellis Pharmaceuticals' Retained Earnings averaged around -$2.9 billion, with its median value being -$2.9 billion (2024).
  • Data for Apellis Pharmaceuticals' Retained Earnings shows a maximum YoY slumped of 78.84% (in 2021) over the last 5 years.
  • Apellis Pharmaceuticals' Retained Earnings (Quarterly) stood at -$1.7 billion in 2021, then plummeted by 39.37% to -$2.3 billion in 2022, then fell by 22.90% to -$2.8 billion in 2023, then declined by 6.97% to -$3.0 billion in 2024, then remained steady at -$3.0 billion in 2025.
  • Its Retained Earnings was -$3.0 billion in Q3 2025, compared to -$3.2 billion in Q2 2025 and -$3.1 billion in Q1 2025.